ArticleFrontiers in pharmacology2025
Associated factors, emergency department visits, and hospitalization days of receiving adjunctive Chinese herbal medicine therapy for patients with non-small cell lung cancer: a nationwide cohort study in Taiwan.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cancer prevention and treatment, particularly lung cancer, remain major healthcare challenges in Taiwan and globally. This study investigates factors and healthcare utilization patterns associated with adjunctive Chinese herbal medicine (CHM) therapy in non-small cell lung cancer (NSCLC) patients. Methods: Using Taiwan's National Health Insurance Research Database and the Taiwan Cancer Registry, we conducted a retrospective cohort study of non-small cell lung cancer patients diagnosed between 2007 and 2013. Descriptive analysis, propensity score matching, and regression models were employed to assess CHM therapy utilization and its impact on emergency department visits and hospitalization days. Results: Among 43,122 non-small cell lung cancer patients, 5.76% received adjunctive CHM therapy, with the majority at stage IV cancer. Factors such as cancer stage, age, gender, marital status, education level, monthly salary, degree of urbanization, severity of comorbidity, comorbid diseases, hospital ownership, experience of using Chinese medicine, chemotherapy status, and years of diagnosis are significantly associated with whether NSCLC patients receive adjunctive CHM therapy. Patients receiving adjunctive CHM therapy for 181-365 days reduced emergency department visits by 16% (OR = 0.84, 95%CI: 0.74-0.95) and shortened hospitalization days by 17% (Ratio = 0.83, 95%CI: 0.75-0.91). Conclusion: Prolonged adjunctive CHM therapy, particularly for 181-365 days, is associated with decreased healthcare utilization among non-small cell lung cancer patients. These findings suggest a potential role for extended CHM therapy in managing NSCLC and warrant consideration by clinical teams.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.